Recombinant Human MICA Fc Chimera Avi-tag Protein, CF

When Recombinant Human NKG2D Fc Chimera (Catalog # 1299-NK) is immobilized at 1 μg/mL (100 μL/well), the concentration of Biotinylated Human MICA Fc Chimera Avi-tag (Catalog # AVI1300) that produces 50% of the optimal binding response is found to be approximately 7.5‑45 ng/mL.

2 μg/lane of Biotinylated Recombinant Human MICA Fc Chimera Avi-tag (Catalog # AVI1300) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 85-100 kDa and 170-200 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human MICA Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human NKG2D Fc Chimera (Catalog # 1299-NK) is immobilized at 1 μg/mL (100 µL/well), the concentration of Biotinylated Recombinant Human MICA Fc Chimera Avi-tag (Catalog # AVI1300) that produces 50% of the optimal binding response is found to be approximately 7.5-45 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human MICA protein
  

  Human MICA (Ala23-Gln308) Accession # NP_001170990.1	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag

• Accession #: NP_001170990.1
• N-terminal Sequence: Ala23
• Structure / Form: Disulfide-linked homodimer, biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 61 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 85-100 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human MICA Fc Chimera Avi-tag Protein, CF

• FLJ60820
• MGC111087
• MICA
• PERB11.1

Background

MICA (MHC class I chain-related gene A) is a transmembrane glycoprotein that functions as a ligand for human NKG2D. A closely related protein, MICB, shares 85% amino acid identity with MICA. These proteins are distantly related to the MHC class I proteins. They possess three extracellular Ig‑like domains, but they have no capacity to bind peptide or interact with beta 2-microglobulin. The genes encoding these proteins are found within the Major Histocompatibility Complex on human chromosome 6. The MICA locus is highly polymorphic with more than 50 recognized human alleles. MICA is absent from most cells but is frequently expressed in epithelial tumors and can be induced by bacterial and viral infections. MICA is a ligand for human NKG2D, an activating receptor expressed on NK cells, NKT cells, gamma δ T cells, and CD8⁺ alpha beta T cells. Recognition of MICA by NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells. MICA recognition is involved in tumor surveillance, viral infections, and autoimmune diseases.

1. Groh, V. et al. (2001) Nature Immunol. 2:255.
2. Stephens, H. (2001) Trends Immunol. 22:378.
3. Bauer, S. et al. (1999) Science 285:727.
4. Groh, V. et al. (2002) Nature 419:734.
5. Steinle, A. et al. (2001) Immunogenetics 53:279.
6. Pende, D. et al. (2002) Cancer Res. 62:6178.
7. NKG2D and its Ligands (2002) http://www.RnDSystems.com

Bioinformatics

• Uniprot:
  • NP_001170990.1()